European journal of nuclear medicine and molecular imaging · 2025
[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.
Клиническое исследование II фазыКлиническое исследование III фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Versweyveld Louis, Delva Aline, Cohilis Marie, Deroose Christophe M, Van Weehaeghe Donatienne, Koole Michel, Vandenberghe Wim, Van Laere Koen
Аннотация
PURPOSE: Cardiac noradrenergic denervation visualized by meta-[123I]iodobenzylguanidine ([123I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[18F] fluorobenzylguanidine ([18F]MFBG) PET demonstrated favorable imaging characteristics compared with [123I]MIBG scintigraphy for neuroendocrine tumors. We assessed [18F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
METHODS: For dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3-4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG.
RESULTS: Mean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM VT from full 120-min datasets. [18F]MFBG HMR correlated the same to [18F]MFBG VT (ρ=0.88, p=0.007) for 10-30-min as for 100-120-min postinjection time intervals. [123I]MIBG HMR correlated more strongly to [18F]MFBG VT at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection.
CONCLUSION: [18F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049.
METHODS: For dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3-4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG.
RESULTS: Mean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM VT from full 120-min datasets. [18F]MFBG HMR correlated the same to [18F]MFBG VT (ρ=0.88, p=0.007) for 10-30-min as for 100-120-min postinjection time intervals. [123I]MIBG HMR correlated more strongly to [18F]MFBG VT at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection.
CONCLUSION: [18F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049.